Hi ,
Frustrating for all holders but 3 trial updates in 3 months including the Keynote.
So far Cavatak is leading the field in combination. 67% Orr.
If it's translated to bigger trial numbers it's a very big commercial op.
The company told us that just have to believe or sell.
Aloha.
Ps or buy more.
Gilead buys Kite Pharma for $11.9 BN, page-17
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)